Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVN058 Effect on Mismatch Negativity in Schizophrenia
NCT03669250Phase 1Completed
- Sponsor
- Cerevance
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CVN058 in schizophrenia (3 arms), sponsored by Cerevance. Primary endpoint: Mean Amplitude of Duration of Auditory Mismatch Negativity (MMN). Started Nov 2018; status: completed.
02
Drugs
CVN058
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03669250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669250.